Our findings strongly encourage development of BMI-1–targeted therapies for patients with NSCLC carrying mutant EGFR, suggesting an exciting opportunity for precision medicine in the genetically complex NSCLC disease. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.